Impact of early tirofiban administration on myocardial salvage in patients with acute myocardial infarction undergoing infarct-related artery stenting

Cardiology

Volumn 106, Issue 4, 2006, Pages 264-269

  Emre, Ayse ^a,b   Ucer, Ekrem ^a   Yesilcimen, Kemal ^a   Bilsel, Tuba ^a   Oz, Dilaver ^a   Sayar, Nurten ^a   Terzi, Sait ^a   Akbulut, Tamer ^a   Ersek, Birsen ^a  

^a DR SIYAMI ERSEK THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b NONE   (Turkey)

Author keywords

Early tirofiban; Myocardial salvage; Primary stenting

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; TIROFIBAN;

ACUTE HEART INFARCTION; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BALLOON DILATATION; BLEEDING; CARDIOTOXICITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; CORONARY STENTING; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; EARLY INTERVENTION; FEMALE; HEART INFARCTION SIZE; HEART SCINTISCANNING; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NONSURGICAL INVASIVE THERAPY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SALVAGE THERAPY; SYMPTOM; THERAPY DELAY; THROMBOCYTOPENIA;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COMBINED MODALITY THERAPY; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RADIOPHARMACEUTICALS; SALVAGE THERAPY; STENTS; TECHNETIUM TC 99M SESTAMIBI; TREATMENT OUTCOME; TYROSINE;

EID: 33751113323     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093408     Document Type: Article

References (23)

1. Grines CL, Cox DA, Stone GW, et al: Coronary angioplasty with or without stent implantation for acute myocardial infaction. N Engl J Med 1999;341:1949-1956.
2. Saito S, Hosokawa G, Tanaka S, Nakamura S: Primary stent implantation is superior to balloon angioplasty in acute myocardial infarction: final results of the Primary Angioplasty versus Stent implantation in Acute myocardial infarction (PASTA) trail. Cathet Cardiovasc Interv 1999;48:262-268.
3. Stone GW, Grines CL, Cox DA, et al., for the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators: Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-966.
4. Montalescot GP, et al., for the ADMIRAL Investigators: Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. J Am Coll Cardiol 2001;344:1895-1903.
5. Neumann FJ, Blasini R, Schmitt C, et al: Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary artery stents in acute myocardial infarction. Circulation 1998;98:2695-2701.
6. Schömig A, Kastrati A, Dirshinger J, et al: Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. N Engl Med 2000;343:385-391.
7. Lee DP, Herity NA, Hiatt BL, et al: Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes. Results of the Tirofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) Pilot Trial. Circulation 2003;107:1497-1501.
8. Montalescot G, Borentain M, Payot L, Collet JP, Thomas D: Early vs. late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA 2004;292:362-366.
9. Gibbons RJ, Christian TF, Hopfenspirger M, Hodge DO, Bailey KR: Myocardium at risk and infarct size after thrombolytic therapy for acute myocardial infarction. İmplications for the design of randomized trials of acute intervention. J Am Coll Cardiol 1994;24:616-623.
10. Gibbons RJ, Miller TD, Christian TF: Infarct size measured by single photon emission computed tomographic imaging with 99m Tc-sestamibi: a measure of efficacy of therapy in acute myocardial infarction. Circulation 2000;101:101-108.
11. Braunwald E: Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival: should the paradigm be expanded? Circulation 1989;79:441-444.
12. TIMI Study Group: The Thrombolysis in Myocardial Infarction (TIMI) trial: phase 1 findings. N Engl J Med 1985;312:932-936.
13. Gibson CM, Cannon CP, Daley WL, et al: TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996;93:879-888.
14. Gibson CM, Cannon CP, Murphy SA, et al: The relationship of the TIMI myocardial perfusion grade to mortality following thrombolytic administration. Circulation 2000;101:125-130.
15. Bovill EG, Terrin ML, Stump DC, et al: Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II trial. Ann Intern Med 1991;115:256-265.
16. Kastrati A, Dirschinger J, Mehilli J, et al: Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patietns with acute myocardial infarction: a randomized trial. Lancet 2002;359:920-925.
17. Topol EJ: Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation 1998;97:211-218.
18. Roe MT, Ohman EM, Maas AC, et al: Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. J Am Coll Cardiol 2001;37:9-18.
19. Gassler J, Topol EJ: Reperfusion revisited: beyond TIMI 3 flow. Clin Cardiol 1999;22(suppl 8):IV-20-IV-29.
20. Mukherjee D, Moliterno DJ: Achieving tissue-level perfusion in the setting of acute myocardial infarction. Am J Cardiol 2000;85:39C-46C.
21. Lee CW, Moon D-H, Hong M-K, et al: Effect of abciximab on myocardial salvage in patients with acute myocardial infarction undergoing primary angioplasty. Am J Cardiol 2002;90:1243-1246.
22. Bellandi F, Maioli M, Leoncini M, Toso A, Dabizzi RP: Early abciximab administration in acute myocardial infarction treated with primary coronary intervention. Int J Cardiol 2006;108:36-42.
23. Kabbani SS, Aggarwal A, Terrien EF, DiBattiste PM, Sobel BE, Scheneider DJ: Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol 2002;89:647-650.